Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest as assessed by right heart catheterization (RHC). The symptoms of PH are non-specific and mainly related to progressive right ventricular (RV) dysfunction. In some patients the clinical presentation may be related to mechanical complications of PH and the abnormal distribution of blood flow in the pulmonary vascular bed, include hemoptysis related to rupture of hypertrophied bronchial arteries. Hemoptysis is a serious complication that is rarely reported in patients with pulmonary arterial hypertension (PAH). Hemoptysis severity ranges from mild to very severe leading tosudden death. Hemoptysis are reported to be a terminal stage of a complication due to PAH with prevalence is variable, from 1% to 6%. Although the incidence is quite rare, the presence of recurrent hemoptysis in patients with pulmonary hypertension is a sign of poor prognosis. Bronchial artery embolization is suggested as an acute emergency procedure in the case of severe hemoptysis or as elective intervention in cases of frequent mild or moderate episodes.
Microscopically, PAH is characterized by intimal hyperplasia, hypertrophy of the tunica media, thickening of the tunica adventitia, and endothelial proliferation. The disease was first discovered by Dr. Ernst von Romberg in 1891. 2, 3 The incidence of PAH is very rare, where in France the incidence is only 15 cases for every million people. 2, 3 Hemoptysis is a serious complication that is rarely reported in patients with pulmonary arterial hypertension (PAH). Hemoptysis is reported to be a terminal stage of a complication due to PAH. The incidence of hemoptysis in PAH patients remain uncertain and tend to be unreported. Similarly, the patho-mechanism of hemoptysis in PAH remains uncertain. 4 Mortality associated with hemoptysis in PAH is influenced by multifactorial. Some evidence suggests that patients with PAH who are associated with congenital heart disease have a better prognosis for their hemoptysis complications than other PAH types. However, the underlying mechanisms of this condition remain unknown. 4 From the Chest Computed Tomography examination showsa dilation of the pulmonary truncus with diameter± 3.59 cm, dilatation of the right pulmonary artery with diameter± 2.69 cm, dilatation of the left pulmonary artery with diameter± 2.51 cm, and dilatation of the bilateral pulmonary artery branches. The diameter of the pulmonary truncus is greater than the ascending aortic aorta; There is enlargement of the right atrium and the right ventricle. Conclusion: Dilatation of the pulmonary artery that supports the diagnosis of pulmonary hypertension ( Figure 4 ).
Patients have also performed right heart catheterization in the previous hospitalization (April 20, 2015), with results: Primary pulmonary hypertension. Pre O2 test: mPAP = 98 mmHg, Pulmonary Artery Resistance Index (PARI) = 39. Post O2 test: mPAP = 99 mmHg,PARI = 35. Conclusion: primary pulmonary hypertension, high resistance, non reactive with O2 test.
Patients were diagnosed with primary pulmonary arterial hypertension non-reactive O2 test, observation of hemoptysis suspected to be associated with pulmonary hypertension, suspected Health Care-Associated Pneumonia (HCAP) andhypokalemia. The treatments were: sildenafil 40 t.i.d. mg, digoxin 0.25 mg q.i.d., furosemide 20 mg q.i.d., iloprost nebulizer 2.5 mcg q.i.d., Aspar K 1 tablet q.i.d., intravenous ceftazidime 1 gr t.i.d., intravenous ciprofloxacin 400 mgb.i.d.. subtypes, as shown in Table 1 . 1, 6 Based on the 2015 ESC/ERS Guidelines of Pulmonary Hypertension, diagnosis of Pulmonary Hypertension is established by following the algorithm flow as shown in Table 1 .
Based on the algorithm flow of the ESC guideline, anamnesis and physical examination is the initial modality in diagnosing Pulmonary Hypertension.
But often the disease at an early stage is usually asymptomatic. The disease usually progresses with symptoms that vary widely, ranging from mild to severe. Generally patients complain of shortness of breath that is getting worse, malaise, unproductive cough, fainting or syncope, peripheral edema and sometimes hemoptysis, which is rare in most patients.
There is usually no symptom of orthopnea and paroxysmal nocturnal dyspnea. 1, 7 Physical examination is relatively insensitive to make the diagnosis, but it can help to rule out the differential diagnosis. If on lung examination found wheezing and rales, should be considered the possibility of bronchial asthma, bronchitis or fibrosis. Rales as seen in congestive and also cardiomegaly. 9 The chest X-ray of patients proposed in this case report supports the presence of pulmonary hypertension, wherein from chest X-ray image there is presence ofcardiomegaly (RV dilatation). 
P a t h o p h y s i o l o g y o f P u l m o n a r y A r t e r y Hypertension
Pulmonary arterial hypertension (PAH) is a serious disease in which there is progressive pulmonary vascular resistance that can lead to right ventricular failure and death. Microscopically, PAH is characterized by intimal hyperplasia, hypertrophy of the tunica media, thickening of the tunica adventitia, and endothelial proliferation. In PAH there is an increase in pulmonary vascular resistance resulting in decreased right ventricular function due to afterload. The main cause of increased vascular resistance is remodeling due to excessive cell proliferation and decreased apoptosis. In addition, vasoconstriction plays an important role in about 20% of patients. 3, 10 In PAH occurs various pathological changes such as endothelial dysfunction, decreased apoptosis or proliferation ratio of pulmonary artery smooth muscle cells, tunica intima and media thickening, tunica adventitia abnormalities, and activation of excessive metalloproteases adventitious that similar to cancer and atherosclerosisprocess. In PAH, production of vasoconstrictors such as endothelin and thromboxane by endothelium increases, but on the other hand there is a decrease in the production of vasodilators such as prostacyclin. 3, 13 In addition, in the lumen of a patient's blood vessel with PAH, an elevated plasma serotonin level was found. Serotonin can stimulate the proliferation of smooth cardiac muscle cells and it is an important sign in the pathogenesis of PAH.
Nitric oxide (NO) produced in the endothelial is a vasodilator that will inhibit platelet activation and vascular smooth muscle cell proliferation formed from three nitric oxide isoforms (NOs / S / NOS3).
However, the role of NO in PAH pathophysiology remains unclear. Pulmonary arterial hypertension has a poor prognosis and high mortality, despite adequate treatment. 13, 14 Clinically, in pulmonary arterial hypertension 
Pathophysiology of Hemoptysis in Pulmonary Artery Hypertension
Hemoptysis is defined as a coughing of blood whose source originates from the lungs or bronchial tubes, as a result of pulmonary or bronchial haemorrhage. Hemoptysis is divided into massive and non-massive based on the coughed blood volume. However, there is no Hemoptysis is a serious complication that is rarely reported in patients with pulmonary arterial hypertension (PAH). Hemoptysis is reported to be a terminal stage of a complication due to PAH. The incidence of hemoptysis in PAH patients remains uncertain and tends to be unreported. Similarly, the patho-mechanism of hemoptysis in PAH remains uncertain. 4 Pulmonary arterial hypertension (PAH) is a pathological condition whose primary cause gene are likely to have unstable pulmonary and bronchial blood vessels, thus increasing the risk of rupture of the blood vessels resulting in hemoptysis. 5, 4 In patients presented in this case report, 
Treatment of Hemoptysis Associated with Pulmonary Hypertension
In the 2015 ESC/ERS Guidelines for pulmonary hypertension, an algorithm of pulmonary arterial hypertension therapy is presented. Currently, several studies for the treatment of pulmonary hypertension have been performed, such as class of vasodilators, prostanoids, nitric oxide, phosphodiesterase inhibitors, endothelin receptor antagonists and anti-coagulants treatment. 1, 3 Based on existing studies, it was found that in patients with idiopathic pulmonary arterial hypertension who responded well to acute vasodilator (oxygen test) during right heart catheterization, only a small proportion responded well to calcium channel blockers.
Calcium-blocking drugs have been studied in patients with pulmonary hypertension, including nifedipine, diltiazem and amlodipine. Selection of calcium-blocking drugs was based on the patient's initial heartbeat, whereas in patients with relative bradycardia, nifedipine and amlodipine were selected, whereas patients with relative tachycardia were given treatment options with diltiazem. 17 Rich et al., 1992 studied the use of Calcium Blockers in PAH patients 95% of patients survived for 5 years. Use of verapamil should be avoided because of its negative inotropic effect.
The use of the above drug causes significant adverse events such as severe hypotension that can be life-threatening to the patient, requiring rigorous monitoring of patients' hemodynamics. 18 In patients reported in this case report were not treated with a calcium-blocker group because from an acute vasodilator test (oxygen test) showed non-reactive results. Sildenafil, including the phosphodiesterase inhibitor group, is a specific phosphodiesterase type 5 inhibitor. Formerly known as a drug used for erectile dysfunction. The study of 278 patients with idiopathic PAH and PAH with connective tissue abnormalities or with corrected cardiac congenital abnormalities, using placebo or sildenafil (20.40 and 80 mg) administered orally three times daily for 12 weeks. In the group using sindenafil there was a decrease in mean artery pulmonary pressure (mPAP). 20 The FDA approved sildenafil to decrease pulmonary artery pressure in PAH at a dose of 20 mg three times daily. Higher doses can mPAP, but high doses in the long term cause side effects dizziness, headache, epistaxis, nausea and vomiting. 21 Hemoptysis is known to be one of the complications of pulmonary hypertension.
Although the incidence is quite rare, the presence of recurrent hemoptysis in patients with pulmonary hypertension is a sign of poor prognosis. 
Prognosis of Hemoptysis Associated with Pulmonary Hypertension
The prognosis of PAH is usually worse because it is generally caused by other diseases.
Usually, patients realize if they have pulmonary hypertension after the clinical symptoms appear, which that means the patient is already in an advanced stage. If it was diagnosed earlier, the prognosis will be better, at least in terms of reducing symptoms. Hemoptysis is known to be one of the complications of pulmonary hypertension.
Although the incidence is quite rare, the presence of recurrent hemoptysis in patients with pulmonary hypertension is a sign of poor prognosis. 4 
